Clinical trials
Relapsed or Refractory Acute Myeloid Leukemia (AML) clinical trials
Below are recruiting relapsed or refractory acute myeloid leukemia (aml) clinical trials, each written for real people, not researchers. We’re tracking 1,349 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04901702RecruitingPhase 1/Phase 2
Onivyde plus talazoparib or temozolomide for resistant solid tumors
This trial tests whether adding Onivyde to either talazoparib or temozolomide can shrink or control hard-to-treat (refractory or recurring) cancers in children and young adults. It aims to find safer dosing first, then look at how well the treatment works—especially for Ewing sarcoma.
Palo Alto, CaliforniaAges 1–30 - NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
Birmingham, AlabamaAges 1–30 - NCT05039801RecruitingPhase 1
Study drug IACS-6274 tested for advanced solid tumors
This Phase 1 study tests the experimental drug IACS-6274, sometimes with bevacizumab and paclitaxel, in people with advanced solid tumors that have not responded to standard treatments. It aims to find the safest dose and to learn whether the treatment can shrink or control cancer for certain tumor mutation types.
Houston, TexasAges 18 years+ - NCT07816666RecruitingPhase 3
Maintenance treatment for relapsed ovarian cancer
This trial tests a new drug called torvutatug samrotecan, given alone or with bevacizumab, as maintenance therapy after chemotherapy for ovarian cancer that has come back. It aims to see if this treatment can help keep the cancer from growing longer.
Anchorage, AlaskaAges 18 years+ - NCT07365306RecruitingPhase 2
Epcoritamab with chemo before stem cell transplant for DLBCL
This trial tests a combination of drugs — epcoritamab, rituximab, gemcitabine, and oxaliplatin — as a ‘salvage’ therapy for people with diffuse large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to shrink the lymphoma enough so you can go on to a stem cell transplant using your own cells.
Duarte, CaliforniaAges 18 years+ - NCT02863692Recruiting
Registry study for chronic lymphocytic leukemia patients
This study is a registry that collects information about people with certain types of leukemia. It may help researchers understand the disease course and how patients are treated, including people who are newly diagnosed, currently treated, referred for transplant, or have relapsed.
Dresden, SaxonyAges 18 years+ - NCT07690761Enrolling by invitationPhase 2
Rituximab and Zanubrutinib for hairy cell leukemia
This trial tests a combination of two targeted drugs, rituximab and zanubrutinib, for people with hairy cell leukemia or its variant. It aims to see if this therapy works for those who have already had one type of chemotherapy or who cannot take a standard treatment called purine analogs.
HaifaAges 18 years+ - NCT04513639RecruitingPhase 2/Phase 3
Checking treatment for multiple myeloma after MRD becomes negative
This study looks at whether people with newly diagnosed multiple myeloma can safely continue or adjust treatment after they reach “MRD-negative,” meaning very low signs of disease in the bone marrow. It may help reduce the chance of relapse while avoiding unnecessary treatment for some patients.
ÅlesundAges 18–75 - NCT06430424Recruiting
Study of body markers in recurrent glioblastoma
This study looks at special markers in the blood and tumors of people whose glioblastoma has come back. It may help doctors understand why the cancer returns and how to treat it better.
BordeauxAges 18 years+ - NCT06530576RecruitingPhase 2
Thalidomide for symptomatic large granular lymphocytic leukemia
This trial tests the drug thalidomide for people with symptomatic large granular lymphocytic leukemia (LGLL), a rare blood cancer. It aims to see if thalidomide can help control the disease and improve symptoms like low blood counts or an enlarged spleen.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06508463RecruitingPhase 1
Viral therapy for peripheral T-cell lymphoma
This study tests an experimental virus therapy given through a vein for people with a type of lymphoma called peripheral T-cell lymphoma that has come back or not responded to treatment. The virus is designed to infect and destroy cancer cells. Some patients may also receive another drug called cemiplimab as part of a combination group.
Scottsdale, ArizonaAges 18 years+ - NCT05959434RecruitingPhase 2
Therapy program to reduce drinking relapse and PTSD symptoms
This Phase 2 study tests a combined therapy approach for people who have both alcohol use disorder and post-traumatic stress disorder (PTSD). It aims to help you process stressful memories and lower the chances of relapse back to heavy drinking.
Charleston, South CarolinaAges 18 years+ - NCT04616560RecruitingPhase 2
New drug for recurrent Wilms tumor, osteosarcoma, and DSRCT
This trial tests a targeted drug called trastuzumab deruxtecan for children and young adults with certain cancers that have come back or not responded to treatment. It may help if your tumor has not responded to standard therapies.
Birmingham, AlabamaAges 12–39 - NCT04414475RecruitingPhase 2
Selinexor plus low-dose steroid for hard-to-treat myeloma
This Phase 2 trial tests selinexor (a targeted anti-cancer medicine) plus low-dose dexamethasone to treat multiple myeloma that has not responded to many prior treatments. It compares selinexor combinations depending on what medicines you’ve already had, aiming to reduce myeloma activity and improve outcomes.
Pátrai, AchaiaAges 18 years+ - NCT00412594RecruitingPhase 2
Cladribine plus rituximab for hairy cell leukemia
This trial tests whether a combination of two medicines—cladribine and rituximab—can treat hairy cell leukemia. You might be able to join if your leukemia is confirmed and you meet timing, blood test, and health requirements.
Houston, TexasAges 18 years+ - NCT07437963RecruitingPhase 1/Phase 2
Iberdomide plus chemoimmunotherapy for neuroblastoma that returned or did not respond
This trial tests adding a new drug called iberdomide to an existing chemoimmunotherapy regimen for children and young adults with neuroblastoma that has come back or not responded to treatment. The goal is to see if the combination is safe and more effective than current treatments.
Oakland, CaliforniaAges 1–30 - NCT07878923Recruiting
Early vs delayed treatment for relapsing multiple sclerosis
This study compares starting treatment with Ocrevus Zunovo right away versus waiting a bit for people who recently had a relapse. The goal is to see if starting sooner helps control the disease better.
Oklahoma City, OklahomaAges 18 years+ - NCT05745285Recruiting
LLS care support program for blood cancer patients
This study looks at whether LLS services and support improve outcomes and the day-to-day experience of care for people with leukemia, lymphoma, myeloma, MDS, or MPN. It’s mainly about matching you to the right support and following your progress for 6 months.
Miami, FloridaAges 18 years+ - NCT07874581Recruiting
Study of MRG003 for small cell lung cancer that has returned
This study tests a new drug, MRG003, for people with a type of lung cancer called small cell lung cancer that has spread or come back after earlier treatment. The goal is to see if this drug can help shrink tumors or slow the cancer's growth.
ShanghaiAges 18 years+ - NCT05947851RecruitingPhase 3
Nemtabrutinib plus venetoclax versus standard add-on therapy
This Phase 3 study tests whether adding nemtabrutinib to venetoclax works better than the usual next treatment approach (venetoclax plus rituximab) in people with relapsed or treatment-resistant CLL/SLL. It may help by improving how well the cancer responds after at least one prior therapy.
Springdale, ArkansasAges 18 years+ - NCT04237675Recruiting
Study of MS relapses after surgery
This study looks at relapses (new or worsening MS symptoms) after surgery in people with multiple sclerosis (MS). It may help researchers understand what triggers relapse after surgery so better care can be planned.
Athens, AtticaAges 18–70 - NCT04771507RecruitingPhase 1/Phase 2
Testing intermittent ibrutinib for advanced chronic lymphocytic leukemia
This trial studies whether taking ibrutinib in a less continuous (“intermittent”) schedule can keep your chronic lymphocytic leukemia (CLL) under control. It’s for people who have already received ibrutinib for at least 6 months and had a good early response, aiming to reduce treatment intensity while tracking safety and cancer control.
TrondheimAges 18 years+ - NCT05022914Recruiting
PSMA PET/CT scan for PSA relapse after prostate surgery
This trial looks at using a PSMA PET/CT scan to better re-check cancer activity in men whose PSA has started rising after prostate removal. If you qualify, the scan may help doctors choose the next best treatment step.
FlorenceAges 18 years+ - NCT04458688Recruiting
Ocrelizumab study for relapsing MS in African Americans and Caucasians
This study looks at how ocrelizumab works in people with relapsing-remitting multiple sclerosis (MS), and it specifically includes African American and Caucasian participants. Your neurologist may already be choosing ocrelizumab as the best standard treatment for you, and the study then follows you with medical visits and MRI scans.
Detroit, MichiganAges 18–60
Hear when a new Relapsed or Refractory Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory acute myeloid leukemia (aml)?
- Yes. Clin2 currently lists 1,349 recruiting relapsed or refractory acute myeloid leukemia (aml) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory acute myeloid leukemia (aml) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory acute myeloid leukemia (aml) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
- Relapsed/Refractory Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Relapsed Acute Myeloid Leukemia
- Leukemia Acute Myeloid - AML
- Newly Diagnosed Acute Myeloid Leukemia (AML)
- Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.